Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study is a single-armed, open-label, single-center phase II trial of signal transduction
inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic
melanoma, and aims to study the efficacy and safety. The primary endpoint is progression-free
survival (PFS) and the second endpoints are overall response rate (ORR), overall survival
(OS), 1-year OS and safety.